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spirates by real  time  PCR
ear Editor,
cinetobacter baumannii has emerged worldwide as an impor-
ant  nosocomial pathogen.1 The carbapenems are highly
ctive  against A. baumannii, but their activity has been threat-
ned  by the widespread of Class D carbapenemases, mainly
XA-23,  which is highly prevalent in Brazil.2
Treatment of patients infected by carbapenem-resistant A.
aumannii  (CRAB) has been very difﬁcult and therapy is usu-
lly  based on polymyxins.3 The use of poymyxins has been
uided  by the isolation of the organism and detection of car-
apenem  resistance. However, ﬁnal results by conventional
icrobiological methods usually take two to three days, which
onsequently  results in a delay in commencing appropriate
herapy for CRAB, which may  potentially contribute to adverse
utcomes  in patients with severe infections such as ventilator-
ssociated pneumonia (VAP).4
In this study, we  aimed to develop a SYBR green-based
eal time PCR (qPCR) to detect the blaOXA-23 gene directly
rom respiratory tract specimens in patients under mechan-
cal  ventilation, potentially serving as a surrogate marker for
he  presence of CRAB in those patients.
Twenty samples of endotracheal aspirates (ETAs), one spec-
men  per patient, obtained from August to December 2010
rom  patients under mechanical ventilation at Hospital São
ucas,  Porto Alegre, Brazil, were analyzed. All samples were
outinely  cultivated and only the growth of ≥105 CFU/mL of A.
aumannii  was  considered positive in ETA culture.
DNA extraction from 200 L of the bacterial suspension
0.5 McFarland standard) and from ∼400 L of ETA samples
ere  carried out using the Invitek RTP DNA/RNA Virus Mini
it  according to the protocol suggested by the manufacturer.
Two  L of the extracted DNA were  used in a total volume
f  25 L of PCR mix  containing SYBR Green II (Invitrogen). For
rimer  design, multiple nucleotide sequences were  aligned to
earch for conserved regions within the blaOXA-23 gene. The
rimers used to amplify the blaOXA-23 gene were  (F: 5′-AAA
AA GTA AAA CGT ATT GGT TTC G-3′ and R: 5′-CCC AAC CAG
CT  TTC CAA AA-3′), which correspond to nucleotides 518–442
sense)  and 724–743 from A. baumannii (accession number
Y795964.1). qPCR was  performed using the LightCycler plat-
orm  (Roche, Germany) and conﬁrmation of the amplicon wasdone  by melting curve analysis (TM ∼ 80 ◦C). The speciﬁcities
of  the primers for the detection of blaOXA-23 gene were  evalu-
ated  by the BLAST search program.  No matches to the primers
were  found other than blaOXA-23. Negative (0.9% sodium chlo-
ride)  and positive controls (an OXA-23 producing A. baumannii
strain  conﬁrmed by direct sequencing analysis) were  used in
each qPCR.
Of  20 ETAs, CRAB isolates were  recovered in 10,
carbapenem-susceptible A. baumannii (CSAB) in three, and
seven  cultures were negative to A. baumannii. The results of
blaOXA-23 qPCR in both colony and ETA are shown in Table 1.
The number of samples analyzed did not allow for a thor-
ough  sensitivity and speciﬁcity evaluation of the qPCR in ETA,
but  concordant result rates between both culture and qPCR
of  ETA and qPCR of the colony and qPCR of ETA were  consid-
ered  satisfactory. Nonetheless, a few disagreements between
results  were  observed. One culture positive specimen for CRAB
presented  negative results for blaOXA-23 in both qPCR of the
colony and ETA. It is possible that carbapenem-resistance in
such isolate was due to other mechanisms (other carbapene-
mases  or by a combination of non-carbapenemases enzymes
plus  porin modiﬁcation and/or efﬂux pump hyperexpression).
A  thorough investigation of other resistance mechanisms to
carbapenems was  beyond the scope of our study. One CRAB
and  one CSAB presented negative result for blaOXA-23 in qPCR
of  the colony, but showed positive qPCR in ETA. Although these
may  be considered false-positive results, we  cannot rule out
the  real presence of a subpopulation of A. baumannii harboring
the  blaOXA-23 gene in the samples, which could not be detected
by  the phenotypic method used to isolate this pathogen from
ETA.  Although the presence of CRAB in lower numbers may
be  simply considered colonization, not considering growth
<105 CFU/mL in our study impaired the interpretation of these
discordant  results.
Overall,  we believe that our ﬁndings support the poten-
tial  use of qPCR to detect the presence of blaOXA-23 gene
directly from ETAs, and possibly the detection of other
carbapenemase-encoding genes, such as blaOXA-143 gene for
example, which has been shown to be highly prevalent in
some  Brazilian Southeastern cities,5 as surrogate marker for
the  presence or absence of CRAB in patients under mechan-
ical  ventilation. The ﬁnal results can be available in a much
494  b r a z j i n f e c t d i s . 2 0 1 3;1  7(4):493–494
Table 1 – Results of quantitative culture, detection of blaOXA-23 gene by real time PCR (qPCR) from colony and endotracheal
aspirate.
Sample Quantitative culture Carbapenem susceptibility Colony qPCR ETA qPCR
1 A. baumannii R Positive Positive
2 A. baumannii R Positive Positive
3 A. baumannii R Positive Positive
4 A. baumannii R Positive Positive
5 A. baumannii R  Positive Positive
6 A. baumannii R  Positive Positive
7 A. baumannii R Positive Positive
8 A. baumannii R Positive Positive
9 A. baumannii R Negative Positive
10 A. baumannii R Negative Negative
11 A. baumannii S Negative Negative
12 A. baumannii S Negative Negative
13 A. baumannii S Negative Positive
14 Negative – – Negative
15 Negative – – Negative
16 Negative – – Negative
17 Negative – – Negative
18 Negative – – Negative
19 Negative – – Negative
20 Negative – – Negative
r
1
2
3
4
5ETA, endotracheal aspirate; R, resistant; S, susceptible.
shorter period (one working day) when compared to conven-
tional  bacterial culture and susceptibility tests results (may
take  up to 72 h or more), consequently saving time to identify
CRAB  in patients with proved or suspected VAP, and poten-
tially  shortening the time for initiating appropriate therapy
for  this difﬁcult to treat infections.
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